Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56bright CD16- natural killer cells

Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56^bright CD16^- natural killer cells

Clin Transl Med. 2021 Aug;11(8):e505. doi: 10.1002/ctm2.505.

Helena Haque Chowdhury^{1

2}, Simon Hawlina^{3

4}, Mateja Gabrijel^{1

2}, Saša Trkov Bobnar^{1

2}, Marko Kreft^{1

2

5}, Gordan Lenart³, Marko Cukjati⁶, Andreja Nataša Kopitar⁷, Nataša Kejžar⁸, Alojz Ihan⁷, Luka Ležaič^{9

10}, Marko Grmek⁹, Andrej Kmetec³, Matjaž Jeras^{1

11}, Robert Zorec^{1

2}

¹ Laboratory of Cell Engineering, Celica Biomedical, Ljubljana, Slovenia.
² Laboratory of Neuroendocrinology - Molecular Cell Physiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
³ Clinical Department of Urology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
⁴ Department of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁵ CPAE, Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
⁶ Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia.
⁷ Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁸ Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁹ Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
¹⁰ Department of Radiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
¹¹ Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

No abstract available